{
    "clinical_study": {
        "@rank": "122850", 
        "arm_group": [
            {
                "arm_group_label": "TD-4208 44 mcg twice daily", 
                "arm_group_type": "Experimental", 
                "description": "TD-4208 inhalation solution 44 mcg twice daily for 7 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo inhalation solution twice daily for 7 days"
            }, 
            {
                "arm_group_label": "TD-4208 175 mcg once daily", 
                "arm_group_type": "Experimental", 
                "description": "TD-4208 inhalation solution 175 mcg once daily, placebo once daily"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of once and twice daily TD-4208 and placebo\n      when administered using a jet nebulizer for 7 days in a cross-over design to patients with\n      moderate to severe chronic obstructive pulmonary disease."
        }, 
        "brief_title": "A 7-Day Cross-over Study of QD and BID TD-4208 in COPD", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Obstructive Pulmonary Disease", 
            "COPD"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject must have a negative pregnancy test, and must be prepared to use effective\n             contraception if of child-bearing potential\n\n          -  Subject is capable of performing reproducible spirometry maneuvers\n\n          -  Subject has post-bronchodilator FEV1/FVC ratio <0.7\n\n          -  Subject has moderate-to-severe stable COPD (Stage 2 or 3 according to the GOLD\n             Guidelines)\n\n          -  Subject has a post-bronchodilator FEV1 greater than or equal to 30% and less than 80%\n             of predicted normal\n\n          -  Subject demonstrates a post-ipratropium FEV1 response \u2265 12% and \u2265 200 mL of\n             pre-ipratropium FEV1 response\n\n          -  Subject has a current or past smoking history of at least 10 pack-years.\n\n        Exclusion Criteria:\n\n          -  Subject has a significant respiratory disease or disorder other than COPD that would\n             affect the interpretation of data from this study\n\n          -  Subject has a history of reactions or hypersensitivity to inhaled anticholinergic or\n             beta-agonist agents\n\n          -  Subject suffers from any medical condition that would preclude the use of inhaled\n             anticholinergic agents\n\n          -  Subject has been hospitalized for COPD or pneumonia within 12 weeks.\n\n          -  Subject requires long-term oxygen therapy (>15 hours a day)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02109172", 
            "org_study_id": "0116"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "TD-4208 44 mcg twice daily", 
                    "TD-4208 175 mcg once daily"
                ], 
                "intervention_name": "TD-4208", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "TD-4208 175 mcg once daily"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic Obstructive Pulmonary Disease", 
            "COPD"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "contact": {
                "last_name": "Spangenthal, M.D.", 
                "phone": "704-342-8143"
            }, 
            "facility": {
                "address": {
                    "city": "Charlotte", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "28207"
                }, 
                "name": "American Health Research"
            }, 
            "investigator": {
                "last_name": "Selwyn Spangenthal, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Cross-Over Study of QD and BID Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease", 
        "overall_contact": {
            "email": "anicholls@theravance.com", 
            "last_name": "Andrew Nicholls, MD", 
            "phone": "650-808-6400"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Weighted mean (0-24) FEV1", 
            "safety_issue": "No", 
            "time_frame": "Following the Day 7 AM dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02109172"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "56 days"
            }, 
            {
                "description": "Timeframes = (0-4h), (0-6h), (0-24h), (0-12h), and (12-24h)", 
                "measure": "AUC FEV1 and derived weighted means for various timeframes", 
                "safety_issue": "No", 
                "time_frame": "Following Day 7 AM dose"
            }, 
            {
                "description": "Serial FEV1 on Day 7/8", 
                "measure": "Serial FEV1", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "Trough FEV1 on Day 8", 
                "measure": "Trough FEV1", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "measure": "Time to achieve 100 mL and 120 mL increase in FEV1 from baseline after the 1st dose", 
                "safety_issue": "No", 
                "time_frame": "Following first dose of study drug"
            }, 
            {
                "description": "Rescue albuterol use (puffs per day) over each week of treatment", 
                "measure": "Albuterol use", 
                "safety_issue": "No", 
                "time_frame": "Days 1-7"
            }
        ], 
        "source": "Theravance, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Theravance, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}